Here's what we explored on the Journal this week.
The Tiny Power Plants Inside Your Cells (Oct 19)
Mitochondria (my-toe-KON-dree-uh) turn food and oxygen into ATP, little energy batteries your cells spend all day. They even carry their own DNA, a leftover from their bacteria days.
Read it
Shoelace Tips for Your Chromosomes: What Telomeres Do (Oct 20)
Telomeres are protective caps on the ends of your DNA, like the plastic tip on a shoelace. They wear down a bit each time a cell divides.
Read it
Zombie Cells: The Cells That Won't Quit (or Leave) (Oct 21)
Senescent cells stop dividing but don't die. When they pile up, their chemical “grumbling” can stir up inflammation nearby.
Read it
Your Body's Repair Crew: Meet the Stem Cells (Oct 22)
Stem cells rebuild you every day, from blood to gut lining. With age, the crew gets smaller and slower.
Read it
Who's researching this
Rubedo Life Sciences is a California biotech company that studies senescent (“zombie”) cells. Its lead candidate, RLS-1496, is a skin cream designed to target those cells. In March 2026, Rubedo reported early results from a small first-in-human Phase 1 study in the Netherlands in adults with psoriasis or eczema, and said a second early-stage study was underway in the U.S. It's still early research, not an approved treatment. (Rubedo press release; EU trial record)
Mentioning a company is not an endorsement or medical advice.
References
- Rubedo Life Sciences press release, March 26, 2026: https://www.rubedolife.com/media-press-release/rubedo-life-sciences-announces-positive-preliminary-phase-1-clinical-trial-results-for-lead-drug-candidate-rls-1496-in-patients-with-plaque-psoriasis-atopic-dermatitis-and-skin-aging/
- EU Clinical Trials Information System, trial 2025-520514-64-00 (protocol RLS-1496-101): https://ctis.eu/trial/2025-520514-64-00
What this is not. Education only. Stories on cells.com are not medical advice. cells.com does not diagnose, treat, prescribe, run laboratory tests, or ship kits.
Simon Ng is the founder of cells.com. He has spent more than a decade on biotech finance executive teams, including at Quark Pharmaceuticals and Adverum Biosciences, and holds an MBA.